Do you include gemtuzumab ozogamicin for any of your newly diagnosed AML patients who are candidates for 7+3 induction chemotherapy?

Topics: Hematologic Malignancies • Medical Oncology • Leukemia • Hematology

Or do you consider addition of this agent in the re-induction setting for refractory disease?

Answer from: Medical Oncologist at Academic Institution

Yes, I regularly add gemtuzumab ozogamicin (3 mg/m2 IV days 1, 4 and 7) to 7+3 (daunorubicin dose should be 60 mg/m2 IV days 1-3) in newly diagnosed AML in the following patient groups based on the ALFA-0701 data (Castaigne, Lancet 2012): 1) Favorable/Intermediate-risk cytogenetics- subset anal...

Comments

Medical Oncologist at Wenatchee Valley Med Center
I'm curious why you recommend it if there is no OS...

Medical Oncologist at UNC Lineberger Comprehensive Cancer Center
The ALFA-0701 study (Randomized phase 3 trial of 7...

Medical Oncologist at Wenatchee Valley Med Center
Thank you.

Medical Oncologist at The Christ Hospital Network
Thanks for the details.

Related Questions